Endpoints News 生物医药· Lei Lei Wu·· 13 天前精选AI 评分65
FDA 批准 J&J 的 Rybrevant 用于头颈癌
J&J’s Rybrevant nets FDA approval in head and neck cancer
AI 导读
FDA 已授予 Johnson & Johnson 的 Rybrevant 加速批准,用于治疗头颈癌患者,这些患者之前已接受过化疗。
推荐理由
FDA 批准 Rybrevant 用于头颈癌,读者可了解该药的最新监管进展。
正文 · 原文
The FDA has granted accelerated approval to Johnson & Johnson’s cancer shot Rybrevant in head and neck cancer that’s come back after previous chemotherapy and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news